Dosing Long-Acting GH Analogs — Practical Considerations for Pediatric Patients

This episode takes a granular look at the practical realities of prescribing and dosing long-acting GH analogs in pediatric patients, from navigating pen device constraints to IGF-1 monitoring and end-of-treatment decision-making.

Dr. Alter opens with a discussion of lonapegsomatropin dosing at 0.24 mg/kg/week. In his practice, dosing tables pre-programmed in Epic (the EHR system) automatically calculate the appropriate fixed dose by weight range, eliminating manual calculation errors. He encourages practices to set up similar tools.

For somapacitan and somatrogon — which use pen delivery devices — dosing becomes more complex. Dr. Alter explains that fixed pen cartridge sizes (e.g., 15 mg for somapacitan) may not align neatly with weight-based calculations. He recommends rounding down to the nearest practical dose (e.g., from 5.3 mg to 5.0 mg) to avoid asking families to perform multi-step arithmetic. As children grow beyond 50 kg, they may occasionally require two injections on the same weekly dosing day.

Dr. Yang highlights a key practical nuance: the three analogs have completely different molecular weights, pharmacokinetics, and delivery systems — meaning dosing in mg/kg/week varies substantially. Lonapegsomatropin: 0.24 mg/kg/week; somapacitan: 0.16 mg/kg/week; somatrogon: 0.66 mg/kg/week. Though the numbers appear different, they reflect different molecular configurations rather than different pharmacologic potency.

The episode then shifts to the question of when to stop GH therapy in pediatric patients approaching growth completion. Dr. Alter explains that the decision is individualized. Today, Dr. Alter continues GH as long as the patient is clearly growing — even with advanced bone age — unless compliance fatigue, family preferences, or height goals have been achieved. A two-heights-the-same rule (no growth over 6 months) signals the true end of linear growth.

In the next episode, “Dosing and Managing Long-Acting GH Therapy in Adults — Clinical Factors, Titration, and Side Effects,” the panel examines adult-specific dosing strategies, titration frameworks, and the side effect profile that distinguishes adult GH therapy from the pediatric experience.